Daily Cosmetic Research Analysis
An open-label randomized trial shows that year-long daily SPF50+ sunscreen use modestly lowers serum 25(OH)D and increases vitamin D deficiency risk versus discretionary use. A de novo pair of short cationic antimicrobial peptides (WKK10, WRR10) demonstrate activity against acne-associated bacteria with low cytotoxicity, supporting cosmeceutical potential. A prospective multicountry study of a dual-applicator cryolipolysis system reports high satisfaction, measurable fat-volume loss, and accepta
Summary
An open-label randomized trial shows that year-long daily SPF50+ sunscreen use modestly lowers serum 25(OH)D and increases vitamin D deficiency risk versus discretionary use. A de novo pair of short cationic antimicrobial peptides (WKK10, WRR10) demonstrate activity against acne-associated bacteria with low cytotoxicity, supporting cosmeceutical potential. A prospective multicountry study of a dual-applicator cryolipolysis system reports high satisfaction, measurable fat-volume loss, and acceptable safety.
Research Themes
- Photoprotection and vitamin D balance
- Noninvasive body contouring technologies
- Antimicrobial peptides for acne/cosmeceuticals
Selected Articles
1. Effect of daily sunscreen application on vitamin D: findings from the open-label randomized controlled Sun-D Trial.
In a population-based, open-label RCT (n=628 analyzed; Australia), routine use of SPF50+ sunscreen for ~1 year lowered serum 25(OH)D by 5.2 nmol/L versus discretionary use and increased vitamin D deficiency prevalence (45.7% vs 36.9%; PR 1.33). Effects were consistent across subgroups; the trial was registered and analyses were blinded to allocation.
Impact: This pragmatic RCT provides real-world evidence that high-SPF daily photoprotection can reduce vitamin D status, informing balanced photoprotection and supplementation strategies.
Clinical Implications: Counsel regular sunscreen users about potential vitamin D insufficiency; consider periodic 25(OH)D testing and supplementation, especially in low-UV seasons or at-risk individuals.
Key Findings
- Routine SPF50+ use for ~1 year reduced serum 25(OH)D versus discretionary use (between-group effect −5.2 nmol/L, 95% CI −7.2 to −3.2).
- Vitamin D deficiency at study end was more prevalent with routine sunscreen (45.7%) than control (36.9%) (prevalence ratio 1.33, 95% CI 1.14–1.55).
- Effects were broadly consistent across baseline vitamin D status, UVR zones, and personal exposure strata; trial registered (ACTRN12621001752853).
Methodological Strengths
- Population-based randomized design with stratified allocation and blinded sample/data analysis.
- Large sample size with prespecified mixed-effects and subgroup analyses across UV exposure strata.
Limitations
- Open-label design may introduce behavior changes and measurement bias.
- Findings from Australia may not generalize to regions with different UV climates or sunscreen use patterns.
Future Directions: Define vitamin D testing/supplementation algorithms for regular sunscreen users; evaluate impacts of different SPF levels, application frequencies, and formulations across latitudes.
BACKGROUND: Sunscreen reduces vitamin D production in experimental studies. It is uncertain whether this translates to real-world settings. OBJECTIVES: To determine if routinely applying high sun protection factor (SPF) sunscreen for a year reduces serum 25-hydroxyvitamin D [25(OH)D] concentration. METHODS: We conducted a population-based open-label randomized controlled trial in Australian participants aged 18-70 years who were not routinely using sunscreen or taking vitamin D supplements. Participants were randomized (1 : 1) using stratified, computer-g
2. Therapeutic potential, antimicrobial activity against acne-causing bacteria, and modes of action of WKK10 and WRR10, novel cationic antimicrobial peptides.
Among 10 designed peptides, WKK10 and WRR10 showed antimicrobial activity against Cutibacterium acnes (MICs 64 and 32 μg/mL, respectively) and staphylococci, with low cytotoxicity to erythrocytes and human cell lines up to 100 μg/mL. FTIR indicated environment-dependent secondary structures, and SEM revealed direct cell-envelope perturbation, supporting membrane-disruptive mechanisms.
Impact: Identifies short, lower-cost antimicrobial peptides with activity against acne-associated bacteria and low cytotoxicity, advancing candidates for topical therapeutics and cosmeceuticals.
Clinical Implications: Supports development of peptide-based topical acne treatments that may reduce reliance on traditional antibiotics and mitigate resistance; formulation and in vivo validation are needed.
Key Findings
- WKK10 and WRR10 inhibited Cutibacterium acnes with MICs of 64 and 32 μg/mL; both were active against Staphylococcus aureus and Staphylococcus epidermidis (MICs as low as 4–8 μg/mL for some peptides).
- Low hemolysis and low cytotoxicity were observed; WKK10 and WRR10 were non-toxic to RAW 264.7, HaCaT, and MRC-5 cells up to 100 μg/mL.
- FTIR showed beta-sheet in aqueous buffer and alpha-helix in TFE; SEM demonstrated cell-envelope disruption, indicating membrane-perturbing mechanisms.
Methodological Strengths
- Comprehensive in vitro profiling across pathogens, cytotoxicity assays in multiple human/murine cell lines, and hemolysis testing.
- Mechanistic corroboration via FTIR secondary-structure analysis and SEM imaging of cell-envelope perturbation.
Limitations
- Findings are limited to in vitro assays; no in vivo efficacy, pharmacokinetics, or skin penetration data.
- Long-term safety, resistance development, and formulation stability were not assessed.
Future Directions: Evaluate in vivo efficacy in acne models, optimize topical formulations and delivery, assess resistance potential and microbiome impact, and perform GLP toxicology.
Although antimicrobial peptides possess potent antimicrobial activities, the high cost of production, based on amino acid length, has limited their therapeutic and cosmeceutical applications. This study aimed to produce and characterize de novo designed antimicrobial peptides derived from WSKK11 and WSRR11 for efficacy against acne-causing bacteria. Ten designed peptides were evaluated for antimicrobial, hemolytic, and cytotoxic activities, as well as, secondary structures by FTIR and modes of act
3. Participant Satisfaction, Effectiveness, and Safety With a Novel Dual-Applicator Cryolipolysis System: A Prospective, Multicountry Study.
In a prospective multicountry study (n=110), 83.3% of evaluable participants were satisfied/very satisfied with midsection results at 12 weeks post-final treatment. Independent reviewers correctly identified baseline versus post-treatment images in 88.0%, mean midsection fat-volume loss was 194.8 mL (p<.001), and 4.5% reported adverse device effects.
Impact: Provides objective volumetric and blinded photographic evidence of effectiveness with simultaneous dual-applicator treatments, informing efficiency and patient satisfaction in aesthetic practice.
Clinical Implications: Supports use of dual-applicator cryolipolysis to reduce session times and expand treatment areas while maintaining efficacy and acceptable safety; informs patient counseling about expected outcomes and rare adverse events.
Key Findings
- 83.3% (80/96) were satisfied/very satisfied with midsection outcomes at 12 weeks post-final treatment.
- Independent reviewers correctly identified baseline vs post images in 88.0% (81/92), indicating visible improvement.
- 3D imaging showed mean midsection subcutaneous fat volume loss of 194.8 mL (SD 492.3) at 12 weeks (p<.001).
- Treatment-emergent adverse device effects occurred in 4.5% (5/110) of participants (7 events).
Methodological Strengths
- Prospective multicountry design with independent blinded photographic review.
- Objective 3D volumetric assessments complementing participant-reported outcomes.
Limitations
- Single-arm study without randomized control; potential selection and expectation biases.
- Short follow-up (12 weeks post-final treatment) limits durability assessment.
Future Directions: Conduct randomized controlled or head-to-head trials versus single-applicator systems, extend follow-up for durability, and characterize predictors of response and adverse events.
BACKGROUND: Cryolipolysis is an effective, well-tolerated noninvasive subcutaneous fat reduction treatment. OBJECTIVE: Assess participant satisfaction, effectiveness, and safety of a dual-applicator cryolipolysis system that can deliver simultaneous treatments. MATERIALS AND METHODS: Adult participants received treatment to the abdomen/flanks (midsection). Participants could also receive treatment to upper arms, thighs, and submental area. Primary end point was participant satisfaction with mids